Dr. Bruce Patterson et al: SARS-CoV-2 S1 (Spike) Protein Found in CD16+ Monocytes Following Acute Sequelae of COVID-19 at 15 Months After Infection

by Paul Alexander

Paul Elias Alexander, PhD, Peter McCullough, MD, Howard Tenenbaum, PhD, DDS, Parvez Dara, MD

Chronic COVID-19 symptoms (long COVID or Post-Acute Sequelae of COVID-19 (PASC)) have emerged in as many as 30% of infected persons. Researchers continue to search for the etiology but it is widely accepted that there are residual symptoms post COVID. Patterson et al. sought to examine the presence of SARS-CoV-2 S1 subunit protein in 46 persons and analyzed T-cell, B-cell, and monocytic subsets in both severe COVID-19 patients and in patients with post-acute sequelae of COVID-19 (PASC). Patterson’s findings raise many alarm bells. Severe acute respiratory syndrome coronavirus 2 binds to cells via the S1 subunit of its spike protein. Patterson et al. found that “the levels of both intermediate (CD14+, CD16+) and non-classical monocyte (CD14Lo, CD16+) were significantly elevated in PASC patients up to 15 months post-acute infection compared to healthy controls (P=0.002 and P=0.01, respectively). A statistically significant number of non-classical monocytes contained SARS-CoV-2 S1 protein in both severe (P=0.004) and PASC patients (P=0.02) out to 15 months post-infection.” 

What does this mean? It means by this timeline that we will never be able to clear spike or its components out of the circulation, and only after many, many years if the 15 months clock begins after each shot. It means if we are willing to infer, that the presence of non-classical monocytes containing SARS-CoV-2 S1 protein (S1 subunit) in both severe and PASC patients at 15 months post infection, could be mirrored by the presence of SARS-CoV-2 S1 protein (S1 subunit) or similar 15 months post COVID vaccination. This is very troubling and raises a host of safety questions given we do not know the implications. Moreover, those in opposition to this hypothesis are limited in any argument to our hypothesis given the vaccine developers failed to study this over the proper duration of follow-up and the FDA failed in their regulatory role to enforce this being studied. Similar to how the FDA failed to ensure ADE was studied or the implications of multiple boosting or the impact of the COVID vaccine on children long term e.g. on the innate immunity of children that typically functions to protect children against SARS-CoV-2 and a range of other pathogen. We just do not know the implications of spike and its components entering the blood stream and where it goes and for how long and exactly what it does, because the vaccine developers Pfizer et al. failed to conducted the proper study.

An important piece to the puzzle emerged from a request to the Japanese regulatory agency. Based on this confidential report (PHARMACOKINETICS: ORGAN DISTRIBUTION CONTINUED pages 6 & 7), we uncovered information of the biodistribution in animals that shows that the vaccine content and lipid nano-particles (and thus potentially the spike protein) does not stay in the shoulder muscle and this finding is very potentially catastrophic. Why? Because the report indicates that the vaccine content (and thus by extension the translated spike protein) gets into the blood stream and could circulate in the blood systemically and accumulate in tissues such as the spleen, bone marrow, liver, adrenal glands, and ovaries. This is seen in the animal model and what we speculated on is now borne out by this data. The biodistribution alarmingly shows that and suggests then that the spike proteins in humans may not stay in the injection site and may indeed travel throughout the body. This is a major concern and can explain the harms and severe outcomes we are seeing post vaccination.